LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by LAVA Therapeutics NV insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for LAVA Therapeutics NV, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hurly Stephen A | Chief Executive Officer | 0 | Nov 17, 2025 | 1 |
| Wilson Karen J | Director | 0 | Nov 17, 2025 | 1 |
| Kiener Peter A | Director | – | Nov 17, 2025 | 1 |
| Powell Fred M | Chief Financial Officer | 0 | Nov 17, 2025 | 1 |
| Noble James | Director | – | Nov 17, 2025 | 1 |
| Dhingra Kapil | Director | 0 | Nov 17, 2025 | 1 |
| Backstrom Jay T. | Director | – | Nov 17, 2025 | 1 |
| Wadlinger Mary E. | Director | – | Nov 17, 2025 | 1 |
| Oliger Christy J. | Director | – | Nov 17, 2025 | 1 |
| Gilde Healthcare Holding B.V. | 10% Owner | 1,947,781 | Oct 20, 2025 | 3 |
| Cooperatieve Gilde Healthcare IV U.A. | 10% Owner | 1,947,781 | Oct 20, 2025 | 3 |
| Versant Venture Capital VI, L.P. | 10% Owner | 0Indirect | Sep 23, 2025 | 0 |
| Versant Vantage I, L.P. | 10% Owner | 0Indirect | Sep 23, 2025 | 0 |
| Versant Vantage I GP, L.P. | 10% Owner | 0Indirect | Sep 23, 2025 | 0 |
| Versant Ventures VI GP-GP, LLC | 10% Owner | 0Indirect | Sep 23, 2025 | 0 |
| Versant Vantage I GP-GP, LLC | 10% Owner | 0Indirect | Sep 23, 2025 | 0 |
| Versant Ventures VI GP, L.P. | 10% Owner | 0Indirect | Sep 23, 2025 | 0 |
| Morris Charles Q | Chief Medical Officer | – | Feb 18, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2025 (view filing)6:58 PM ET | Oct 20, 2015-Oct 17, 2025 | 3,653 daysLate | Gilde Healthcare Holding B.V. and 1 other10% Owner | SSale | −2.87M | $1.47 | −$4.22M | −59.6%1.95M after | 3 lots |
| Oct 15, 2025 (view filing)8:56 PM ET | Oct 15, 2015-Oct 14, 2025 | 3,653 daysLate | Gilde Healthcare Holding B.V. and 1 other10% Owner | SSale | −475.0K | $1.51 | −$718.7K | −9.0%4.82M after | 3 lots |
| Oct 10, 2025 (view filing)6:45 PM ET | Oct 8-10 | 2 days | Gilde Healthcare Holding B.V. and 1 other10% Owner | SSale | −127.0K | $1.56 | −$197.9K | −2.3%5.29M after | 3 lots |
| Sep 23, 2025 (view filing)4:33 PM ET | Sep 19 | 4 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −2.37M | $1.40 | −$3.32M | −100.0%0 after | |
| Sep 23, 2025 (view filing)4:33 PM ET | Sep 19 | 4 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −532.9K | $1.40 | −$746.8K | −100.0%0 after | |
| Sep 18, 2025 (view filing)6:49 PM ET | Sep 16-18 | 2 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −1.04M | $1.49 | −$1.54M | −30.4%2.37M after | 3 lots |
| Sep 18, 2025 (view filing)6:49 PM ET | Sep 16-18 | 2 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −647.8K | $1.49 | −$962.3K | −54.9%532.9K after | 3 lots |